Method of treating bladder and lower urinary tract syndromes

Details Method of treating bladder and lower urinary tract syndromes Method of treating bladder and lower urinary tract syndromes

2007-07-23

2010-12-28

McGarry, Sean (Department: 1635)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S287100, C435S287200

Reexamination Certificate

active

07858312

ABSTRACT:
The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using α1d-adrenergic receptor (α1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as α1dAR selective antagonists.

REFERENCES:
patent: 3994974 (1976-11-01), Murakami et al.
patent: 4063065 (1977-12-01), Wust
patent: 4145363 (1979-03-01), Murakami et al.
patent: 4217305 (1980-08-01), Imai et al.
patent: 4373106 (1983-02-01), Imai et al.
patent: 4558156 (1985-12-01), Imai et al.
patent: 4665095 (1987-05-01), Winn et al.
patent: 4703063 (1987-10-01), Imai et al.
patent: 4724148 (1988-02-01), Sonobe et al.
patent: 4731478 (1988-03-01), Niigata et al.
patent: 4761500 (1988-08-01), Niigata et al.
patent: 4765988 (1988-08-01), Sonobe et al.
patent: 4868216 (1989-09-01), Imai et al.
patent: 4880841 (1989-11-01), Imai et al.
patent: 4987152 (1991-01-01), Imai et al.
patent: 5063246 (1991-11-01), Imai et al.
patent: 5110820 (1992-05-01), Fujikura et al.
patent: 5198587 (1993-03-01), Imai et al.
patent: 5229392 (1993-07-01), George et al.
patent: 5244894 (1993-09-01), George et al.
patent: 5244901 (1993-09-01), George et al.
patent: 5246939 (1993-09-01), George et al.
patent: 5254560 (1993-10-01), George et al.
patent: 5330985 (1994-07-01), George et al.
patent: 5340814 (1994-08-01), Chern et al.
patent: 5380742 (1995-01-01), Sevrin et al.
patent: 5391825 (1995-02-01), Niigata et al.
patent: 5403842 (1995-04-01), Leonardi et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5420130 (1995-05-01), George et al.
patent: 5447916 (1995-09-01), Spellmeyer et al.
patent: 5447958 (1995-09-01), Niigata et al.
patent: 5480871 (1996-01-01), Spellmeyer et al.
patent: 5503843 (1996-04-01), Santus et al.
patent: 5508306 (1996-04-01), Chiu et al.
patent: 5512677 (1996-04-01), Chern et al.
patent: 5538976 (1996-07-01), Okada et al.
patent: 5556753 (1996-09-01), Bard et al.
patent: 5561154 (1996-10-01), Bellamy et al.
patent: 5573908 (1996-11-01), Allen et al.
patent: 5578611 (1996-11-01), Gluchowski et al.
patent: 5591757 (1997-01-01), Fujikura et al.
patent: 5610174 (1997-03-01), Craig et al.
patent: 5714381 (1998-02-01), Bard et al.
patent: 5824680 (1998-10-01), Turner et al.
patent: 5861309 (1999-01-01), Bard et al.
patent: 257787 (1988-03-01), None
patent: 382 935 (1990-08-01), None
patent: 380144 (1990-08-01), None
patent: 594 484 (1994-04-01), None
patent: 0 682 028 (1995-03-01), None
patent: 675109 (1995-10-01), None
patent: 753 511 (1997-01-01), None
patent: 2 703 355 (1993-03-01), None
patent: 2 703 355 (1994-10-01), None
patent: 2 724 382 (1996-03-01), None
patent: 2 724 383 (1996-03-01), None
patent: 72021421 (1972-06-01), None
patent: 72027091 (1972-07-01), None
patent: 73001069 (1973-01-01), None
patent: 73001070 (1973-01-01), None
patent: 74011218 (1974-03-01), None
patent: 49051258 (1974-05-01), None
patent: 49051271 (1974-05-01), None
patent: 54061139 (1979-05-01), None
patent: 6-501713 (1994-02-01), None
patent: 8126491 (1996-05-01), None
patent: WO 94/14769 (1994-07-01), None
patent: WO 95/19357 (1995-07-01), None
patent: WO 96/40136 (1996-12-01), None
patent: WO 97/42956 (1997-11-01), None
patent: WO 99/57131 (1999-11-01), None
De Benedetti et al. (Bioorganic & Medicinal Chemistry, 1997 vol. 5, No. 5:809-816).
Lepor et al, “Effect of Terazosin on Prostatism in Men With Normal and Abnormal Peak Urinary Flow Rates”, Urology 49:476-480 (1997).
Broten et al, “Alpha-1 Adrenoceptor Blockade Inhibits Detrusor Instability in Rats With Bladder Outlet Obstruction”, Monday AM, Adrenergic Pharmacology (2583-2588), FASEB J. 12:A445 (1998)—Abstract No. 2584.
Hampel, C, “Changes in α1 Adrenergic Receptor (AR) Subtype Gene Expression During Bladder Outlet Obstruction of Rats”, The American Urological Association, Inc.® 95thAnnual Meeting, Draft Preview of Abstract #351666, Wednesday, Nov. 10, 1999.
Beduschi et al, “Alpha-Blockade Therapy for Benign Prostatic Hyperplasia: From a Nonselective to a More Selective Alpha1A-Adrenergic Antagonist”, Urology 51:861-872 (1998).
Schulman et al, “Tamsulosin, the First Prostate-Selective α1A-Adrenoceptor1Antagonist”, Eur. Urol. 29:145-154 (1996).
Kawabe et al, “Use of an α1-Blocker, YM-12617, in Micturition Difficulty”, Urol. Int. 42:280-284 (1987).
Walden et al, “Localization of mRNA and Receptor Binding Sites for the α1a-Adrenoceptor Subtype in the Rat, Monkey and Human Urinary Bladder and Prostate”, The Journal of Urology 157:1032-1038 (1997).
Stafford Smith et al, α1-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic receptor subtypes at four distinct levels, Molecular Brain Research 63:254-261 (1999).
Ferguson and Christopher, “Urinary bladder function and drug development”, TIPS 17:161-165 (1996).
Reuther and Aagaard, “α-Adrenergic Blockade in the Diagnosis of Detrusor Instability Secondary to Infravesical Obstruction”, Urol. Int. 39:312-313 (1984).
Hieble et al, International Union of Pharmacology X. Recommendation for Nomenclature of α1-Adrenoceptors: Consensus Update, Pharmaceutical Reviews 47(2):267-270 (1995).
Lepor, H., “Prostate Selectivity of Alpha-Blockers: From Receptor Biology to Clinical Medicine”, Eur. Urol. 29(Suppl 1):12-16 (1996).
Graham et al, α1-Adrenergic Receptor Subtypes Molecular Structure, Function, and Signaling, Circ. Res. 78:737-749 (1996).
Schwinn et al, “Cloning and Pharmacological Characterization of HumanAlpha-1 Adrenergic Receptors: Sequence Corrections and Direct Comparison with Other Species Homologues”, The Journal of Pharmacological and Experimental Therapeutics, 272(1):134-142 (1995).
Price et al, “Expression ofα1-Adrenergic Receptor Subtype mRNA in Rat Tissues and Human SK-N-MC Neuronal Cells: Implications forα1-Adrenergic Receptor Subtype Classification”, Molecular Pharmacology 46:221-226 (1994).
Price et al, “Localization of mRNA for Three Distinct α1-Adrenergic Receptor Subtypes in Human Tissues: Implications for Human α-Adrenergic Physiology”, Molecular Pharmacology 45:171-175 (1993).
Berkowitz et al, “Localization of Messenger RNA for Three Distinct α2-Adrenergic Receptor Subtypes in Human Tissues”, Anesthesiology 81(5):1235-1244 (1994).
Berkowitz et al, “Distribution of β3-adrenoceptor mRNA in human tissues”, European Journal of Pharmacology, Molecular Pharmacology Section 289:223-228 (1995).
Price et al, “Identification, Quantification, and Localization of mRNA for Three Distinct Alpha1Adrenergic Receptor Subtypes in Human Prostate”, The Journal of Urology 150:546-551 (1993).
Maruyama et al, “Discrimination of α1-Adrenoceptor Subtypes in Rat Aorta and Prostate”, Pharmacology 57:88-95 (1998).
Faure et al, “Identification of α1-Adrenoceptor Subtypes Present in the Human Prostate”, Life Sciences 54(21):1595-1605 (1994).
Forray et al, “The α1-Adrenergic Receptor that Mediates Smooth Muscle Contraction in Human Prostate Has the Pharmacological Properties of the Cloned Human α1cSubtype”, Molecular Pharmacology 45:703-708 (1994).
Marshall et al, “Noradrenaline contractions of human prostate mediated by α1A-(α1c-) adrenoceptor subtype”, British Journal of Pharmacology 115:781-786 (1995).
Ford et al, “Pharmacological pleiotropism of the human recombinant α1A-adrenoceptor: implications for α1-adrenoceptor classification”, British Journal of Pharmacology 121:1127-1135 (1997).
Ford et al, “RS-17053 (N-[2-(2-Cyclopropylmethoxyphenoxy)ethyl]-5-chloro-α, α-dimethyl-1H-indole-3-ethanamine hydrochloride), a Selective α1A-Adrenoceptor Antagonist, Displays Low Affinity for Functional ;

Affiliated with

Also associated with

Rating

Method of treating bladder and lower urinary tract syndromes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating bladder and lower urinary tract syndromes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating bladder and lower urinary tract syndromes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4196985